The effectiveness of antacid maintenance therapy in preventing duodenal ulcer (DU) relapse was investigated. Two hundred and fifty one asymptomatic patients with healed DU were stratified into smokers and non-smokers and randomised to receive for one year either placebo, or Maalox TC three tablets (81 mmol) at bedtime (hs), or Maalox TC three tablets in the morning plus three tablets at bedtime (bd) (162 mmol), or cimetidine 400 mg at bedtime. A double dummy technique was used to render the study double blind. In 176 patients evaluable for efficacy, the cumulative relapse at one year was: placebo 57%; Maalox TC hs 39%; Maalox TC bd 23%; cimetidine 25%. Maalox TC bd and cimetidine were equally effective and superior to placebo (p<O.Ol) and bedtime Maalox TC (p<004). The benefit of treatment was significant for the overall sample and for the subgroup of smokers. The results for the non-smokers also supported efficacy for these two treatments but, perhaps because of small sample sizes, these comparisons were not significant. All 251 patients were assessed for safety. Approximately half the patients in each treatment group had adverse events, leading to withdrawal in three, seven, 12, and four patients on placebo, Maalox hs, Maalox bd, and cimetidine respectively. Diarrhoea occurred in 12 patients in Maalox TC bd and eight in each other group. Serum magnesium concentrations were unchanged; aluminium concentrations were higher than baseline at six and 12 months in both antacid groups and at 12 months in the cimetidine group but the differences were not significant. Maalox TC three tablets bd are as effective as cimetidine 400 mg at bedtime in reducing DU relapse and both are superior to placebo.
Patients with previous symptomatic endoscopy proven DU which had been shown endoscopically to have healed within the previous one year were studied, provided they were asymptomatic and ulcer free at endoscopy done less than seven days before starting treatment. The minimum age was 18 and adequate contraceptive methods must have been used by women of childbearing age. The exclusion criteria were: pregnancy; Zollinger-Ellison and related syndromes; hepatic or renal disorders; the presence of significant symptoms from other gastrointestinal disorders which would make it difficult to evaluate efficacy and safety of the trial drugsfor example, severe irritable bowel syndrome; alcoholism; previous anti-ulcer surgery other than closure of perforation; coexistent or previously noted gastric ulcers; presence of other severe illness -for example, cardiorespiratory problems; where the chance of exposure to placebo was felt hazardous or where there seemed to be likely difficulty in the patient continuing in the study; and if patients required concomitant treatment during the study with anticholinergics, salicylates, non-steroidal antiinflammatory drugs, corticosteroids, phenothiazines, or tetracyclines.
The antacid used was Maalox TC tablets (Rorer Group Inc, Fort Washington, Pennsylvania 19034, USA). Each tablet contains aluminium hydroxide gel 600 mg and magnesium hydroxide 300 mg and has a neutralising capacity of 27 mmol.
The patients were stratified into smokers and nonsmokers and then randomised to receive one of four treatments: placebo, Maalox TC three tablets (81 mmol acid neutralising capacity) at bedtime (Maalox hs), Maalox TC three tablets in the morning plus three tablets at bedtime (162 mmol) (Maalox bd) and cimetidine 400 mg at bedtime. A double blind double dummy method was used, involving large white tablets of identical appearance containing antacid or placebo and light green coloured capsules of identical appearance containing 200 mg cimetidine or placebo. The medication was supplied in blister packs containing one day's treatment with instructions to chew three tablets one hour after breakfast and another three tablets at bedtime, followed by two capsules. The decision to regard patients as non-evaluable for efficacy analysis was done before breaking the treatment code.
Subsequently, additional intention-to-treat analyses were done re-including such patients using various theoretically possible outcomes to examine what influence their exclusion had on the conclusions we reached.
Results

NUMBERS, DEMOGRAPHY, AND EVALUABILITY
The 12 centres entered 251 patients into the study. The numbers in each treatment group were: placebo 62, Maalox hs 65, Maalox bd 60, and cimetidine 64 ( Table 1 ). The patients in the four groups were comparable with respect to age, sex ratio, smoking habits, and in the proportion of Caucasians. The length of ulcer history and the time since the last ulcer healed before trial recruitment were shorter in patients on placebo. The number of ulcer recurrences The treatment used for the last ulcer healed was recorded although for a few patients the information was not available because the treatment had been within a clinical trial which remained blind. As there is now evidence that the relapse rate after healing with tripotassium dicitrato bismuthate is lower than after H2 receptor antagonists,91 0 1 we looked specifically at the use of these agents to heal the last ulcer. As will be seen from Table 1 , the vast majority of patients had received H2 receptor antagonists, whilst the numbers who had received the bismuth compound ranged from three on placebo to six on Maalox bd. It therefore seems most unlikely that the choice of previous treatment could have influenced the. outcome of this study.
Data from all patients were evaluated when assessing adverse events of treatment but for efficacy analysis (relapse rates), data from 75 of 251 patients (30%) were exluded for reasons shown in Table 2 . The proportion of non-evaluable patients in each treatment group was similar and these patients were of comparable demography to the remainder of the patients who were included for efficacy analysis.
RELAPSE RATES (Table 3 and the Figure) In patients who relapsed, the ulcer recurrence tended to occur early, particularly on placebo where the six months and 12 months relapse rates were, respect- (Table 3) There was a decreased relapse rate for the placebo group in the non-smokers compared with the smokers (41% compared with 67% at 12 months). Consequently the difference in relapse rates in smokers between those on Maalox bd or cimetidine compared with those on placebo is marked and significant (p<0-01). In non-smokers the relapse rate on these two treatments was also lower than on placebo but not significantly so.
INFLUENCE OF GEOGRAPHY ON RELAPSE RATES (Table 3) The data from the UK and France were pooled (Europe) and compared with the pooled data from USA and Canada (North America). There was a trend towards a higher relapse rate in the North American patients receiving placebo or antacids compared with European patients and an opposite trend in cimetidine patients but the differences were not significant.
INFLUENCE OF CENTRES ON RELAPSE RATES
The numbers of patients entered in the 12 centres varied from one to 44. To examine if any centre had an undue influence on the results, the data were reanalysed 12 times, dropping one centre in turn each time whilst keeping the other 11. The conclusions were unchanged.
INFLUENCE OF DEMOGRAPHIC FEATURES ON RELAPSE RATES
None of the demographic criteria listed in Table 1 affected relapse rates other than smoking and the number of ulcer recurrences in the previous two years. As might be expected, patients with a history of more frequent relapses were more likely to relapse during the study (p<0O04 -Cox Life For patients who did not have a final endoscopy on leaving or completing the study, the time to recurrence was considered the period from the start of therapy to its discontinuation. For patients who had their final endoscopy late but within 21 days of finishing treatment, the examination was treated as though done on time if no recurrence was observed; but if re-ulceration was found, they were considered to have relapsed at the time treatment was discon- Table 4 Relapse rates recalculated by including some or all ofthe patients not considered evaluable for efficacy analysis as shown in Table 3 (Table 5) Approximately half the patients in each treatment group complained of adverse events. Most were gastrointestinal problems of a type to be expected in patients with a history of peptic ulcer or known to be associated with antacid treatment. They were sufficiently troublesome, however, to lead to withdrawal in three, seven, 12, and four patients on placebo, Maalox hs, Maalox bd, and cimetidine respectively.
In some cases, patients discontinued for more than one reason but the primary reasons were considered to be as follows. Placebo: one each because of dyspepsia, nausea, and tachycardialarrhythmia. Maalox hs: one each because of gout, dyspepsia, nausea, headache, and gynaecomastia and two because of nausea and vomiting. Maalox bd: seven because of diarrhoea, three because of dyspepsia, and one each because of pneumonia and nausea. Cimetidine: one each because of abdominal pain, diarrhoea, dyspepsia, and flatulence. Thus diarrhoea was a relatively common reason for patients discontinuing Maalox bd although the overall incidence of diarrhoea, defined as an increased frequency and/or looseness of stools, was 12 in patients on Maalox bd against eight in each of the other treatment groups.
As shown in Table 5 , many patients reported more than one adverse event. Dyspepsia was the commonest occurrence and this was reported most frequently by patients on placebo (19) compared with Maalox hs (14) , Maalox bd (10), and cimetidine (six). (Table 6) The pretreatment median magnesium concentrations were almost identical in the four treatment groups, The pretreatment median aluminium concentrations were identical, 4.0 ng/ml. During treatment, however, there was a rise in patients on the antacids, the median value at six and 12 months being 6.0 ng/ml in patients on Maalox hs and 4-1 and 6 3 ng/ml respectively in those on Maalox bd. These changes were not statistically significant but this may reflect the wide scatter in the values obtained.
Discussion
We have found that Maalox TC tablets given as maintenance therapy, reduce the relapse rate of duodenal ulcer. At a dose of three tablets -that is, 81 mmol at bedtime, the relapse rates were lower than placebo but not significantly so (p=013). But when three tablets were used both in the morning and at bedtime (162 mmol daily) the reduction was marked and similar to that achieved by cimetidine 400 mg hs. We do not know if our results would have improved if the entire 162 mmol had been given at bedtime to produce a more complete neutralisation of nocturnal acid secretion. If antacids act exclusively by acid neutralisation, this may be important. But if antacids have other major actions as well, for example, inhibition of pepsin and bile acids and stimulation of prostaglandin synthesis thereby increasing mucosal defence,' then our twice daily dose schedule may be more appropriate.
Smoking was found to influence relapse rates markedly. In their major study on maintenance therapy comparing cimetidine against placebo, Sontag et al,"' using a retrospective breakdown for smoking, found that ulcer relapse was markedly greater in smokers on placebo and on cimetidine, compared with non-smokers. Using prospective analysis, in which we stratified patients as smokers and non-smokers, we have confirmed Sontag et al's observations that smoking is associated with higher relapse rates amongst placebo treated patients: 67% versus 41%. In fact the benefit of maintenance therapy with either Maalox bd or with ciinctiduine was only statistically significant amongst smokers. Among non-smokers, the same two treatments were associated with lower relapse rates than placebo although the differences were not significant, perhaps because of the small sample size.
In the early duodenal ulcer healing studies done in the USA to evaluate cimetidine, healing on placebo was high and on cimetidine relatively low, compared with the UK.'2 1 ' It was therefore felt that there may be some geographical differences in ulcer behaviour (in addition to other factors).'4 Our results showed, however, that the relapse pattern, on placebo and on active treatment was similar and that maintenance therapy was equally effective in both continents.
Somewhat more side effects leading to discontinuation were seen on antacids compared with cimetidine. Diarrhoea, however, which is perhaps the best known of the side effects was seen with equal frequency in patients on placebo, cimetidine and Maalox hs. On Maalox bd, diarrhoea occurred a little more frequently but was not as closely dose related as expected.
The longterm metabolic consequences of prolonged antacid treatment The principal limitations to using antacids rather than an H2-receptor antagonist for longterm maintenance therapy are the inconvenience of having to chew several tablets and the mild gastrointestinal side effects. This may be offset, however, by the attraction of the lower cost. For example, in the UK six Maalox TC tablets are 28% cheaper than cimetidine 400 mg and a year's cost of treatment is £78.34 and £108.28 respectively; however, the relative costs vary markedly from country to country.
In conclusion, maintenance therapy with Maalox TC three tablets in the morning plus three tablets at bedtime (162 mmol daily) is as effective as cimetidine 400 mg nightly in reducing duodenal ulcer relapse. 
